Blog
RSS FeedPosted by Michael Wonder on 19 Nov 2018
The bizarre world of drug pricing
19 November 2018 - There is no shortage of bad ideas when it comes to the pharmaceutical market. One such ...
Posted by Michael Wonder on 12 Nov 2018
PBAC shows no propensity to support Amgen's innovative method of analysis
12 November 2018 - Amgen's recent submission for blinatumomab (Blincyto) treatment of patients with B-cell precursor acute lymphoblastic leukaemia in haematological ...
Posted by Michael Wonder on 30 Oct 2018
Comparison of U.S. and international prices for top Medicare Part B drugs by total expenditures
25 October 2018 - The prices charged by drug manufacturers to wholesalers and distributors (commonly referred to as ex- manufacturers prices) ...
Posted by Michael Wonder on 09 Oct 2018
Outdated public funding model failing New Zealand patients
9 October 2018 - Publicly funded modern medicines are out of reach for many patients in New Zealand according to ...
Posted by Michael Wonder on 25 Aug 2018
This drug is safe and effective. Wait. Compared with what?
20 August 2018 - Comparative effectiveness research may be the best way to answer questions that patients and physicians face every ...
Posted by Michael Wonder on 21 Aug 2018
FDA analysis shows similar success rates for paediatric trials using clinical and surrogate outcomes
21 August 2018 - An analysis by US FDA officials published earlier this month finds that there is a similar ...
Posted by Michael Wonder on 08 Aug 2018
Comparing the ICERs in medicine reimbursement submissions to NICE and PBAC—does the presence of an explicit threshold affect the ICER proposed?
8 August 2018 - The English NICE and the Australian PBAC require evidence that a new medicine represents value for money ...
Posted by Michael Wonder on 28 Jul 2018
Estimating drug costs: how do manufacturer net prices compare with other common US price references?
27 July 2018 - Drug costs are frequently estimated in economic analyses using wholesale acquisition cost, but what is the best ...
Posted by Michael Wonder on 17 Jul 2018
Are 'breakthrough' drugs as safe as other FDA approved medicines?
17 July 2018 - New research questions the quality of drugs given the "breakthrough therapy" designation by the US FDA. ...
Posted by Michael Wonder on 17 Jul 2018
Private health insurance rankings to give consumers more information about coverage and benchmarks
16b July 2018 - Private health insurance premiums will be ranked in a bid to help consumers figure out exactly ...
Posted by Michael Wonder on 10 Jul 2018
Time to entry for new cancer medicines: from European Union wide marketing authorisation to patient access in Belgium, Estonia, Scotland, and Sweden
10 July 2018 - This study quantified the median time from European Union wide approval to first use for a ...
Posted by Michael Wonder on 07 Jun 2018
UK health spends lags behind EU peers
7 June 2018 - The amount the UK spends on health falls well behind that invested by European peers such ...
Posted by Michael Wonder on 03 May 2018
How the U.S. compares to Europe on biosimilar approvals and products in the pipeline
2 May 2018 - FDA has not approved any biosimilar drug in 2018. ...
Posted by Michael Wonder on 01 May 2018
A comparative review of marketing authorisation decisions in Switzerland, the EU, and the USA
19 April 2018 - In this study we compared Swissmedic’s regulatory marketing authorisation decisions to those of the US FDA ...
Posted by Michael Wonder on 24 Jan 2018
Characteristics of interim publications of randomised clinical trials and comparison with final publications
23 January 2018 - Publication of interim results of randomised trials can be consequential, potentially undermining trial integrity by unblinding or ...